HAYWARD, Calif., March 12 /PRNewswire-FirstCall/ -- Thermage, Inc. (NASDAQ:THRM), a leader in non-invasive tissue tightening in the aesthetic industry, today announced it has begun initial shipments of its ThermaTip(TM) CL treatment tips for use in the Company's cellulite procedure. The procedure noticeably reduces the appearance of cellulite after just a single treatment. The treatment tip and procedure are the result of 21 months of clinical and technological development and use the FDA cleared ThermaCool(R) system for the temporary improvement in the appearance of cellulite.
"We began shipments of our ThermaTip CL treatment tip on track and within the timeframe we expected," said Stephen J. Fanning, Chairman of the Board, President and Chief Executive Officer at Thermage. "Cellulite offers a new market opportunity for our Company and we expect the new tip to provide a solid contribution to our revenue in 2008." The ThermaTip CL and cellulite procedure by Thermage incorporate the Company's patented monopolar capacitive radiofrequency technology. The advanced deep heating ThermaTip CL rebuilds collagen connective tissues and improves blood flow to the tissue helping to smooth the appearance of the skin's surface.
About Thermage Thermage's innovative technology provides a unique non-invasive procedure designed to tighten and contour skin, significantly expanding the non-invasive aesthetic applications physicians can offer to the rapidly growing "anti- aging" market. For more information about Thermage, call 1-510-259-7117 or log on to http://www.thermage.com/.
This press release may contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 including the statement regarding revenue contribution of the cellulite treatment tip. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause Thermage's actual results to differ materially from the statements contained herein including the risk that the new tip does not achieve commercial acceptance or that such acceptance is delayed, among other risks. Further information on potential risk factors that could affect Thermage's business are detailed in the Company's Form 10-Q for the period ended September 30, 2007. Undue reliance should not be placed on forward-looking statements, which speaks only as of the date they are made. Thermage undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.
Results vary from subtle to dramatic. Generally improvements may be immediately visible and continue to improve for up to six months. Results are long lasting and depend on your skin condition and the aging process. DATASOURCE: Thermage, Inc.
CONTACT: Investor, Douglas Sherk, or Jenifer Kirtland, +1-415-896-6820, or Media, Steve DiMattia, +1-646-201-5445, all of EVC Group, Inc. for Thermage, Inc.
Web site: http://www.thermage.com/
|